Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
One of the main tasks of modern complex therapy of rheumatoid arthritis (RA) is to improve the quality of life of patients. To do this, it is necessary not only to achieve remission or low activity, but also to successfully control the main, most painful, manifestations of the disease. Therefore, wh...
Saved in:
| Main Authors: | A. E. Karateev, A. M. Lila, T. S. Panevin, A. S. Potapova, A. S. Semashko, A. O. Bobkova, V. N. Amirjanova, E. G. Zotkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-09-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01) -
Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01) -
Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01) -
Features of clinical manifestations of rheumatoid arthritis in patients after failure of conventional synthetic disease-modifying antirheumatic drugs therapy depending on the signs of central sensitization
by: A. S. Potapova, et al.
Published: (2023-04-01) -
Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)